Mepolizumab (Nucala)

Mepolizumab (Nucala) is covered only for the FDA‑approved indications—add‑on maintenance for severe eosinophilic asthma (age ≥6) and treatment of adult EGPA—and is not covered for non‑FDA uses. Coverage requires documented blood eosinophils ≥150 cells/µL within 6 weeks, specified prior therapy (≥3 months of controller regimens for asthma; ≥4 weeks of corticosteroid trial for EGPA), prescriber specialty consultation, dosing every 4 weeks, initial 6‑month approval and 12‑month renewals contingent on documented clinical response.

"Approval duration limits: initial approval duration 6 months; renewal approval duration 12 months."

Sign up to see full coverage criteria, indications, and limitations.